Arthritis
-
FDA endorses efficacy but not safety of Novartis drug for gouty arthritis
An advisory committee of the Food and Drug Administration (FDA) has voted in favor of the overall efficacy but not the overall safety of ACZ885 (canakinumab) to treat gouty arthritis attacks in patients who cannot obtain adequate relief with non-ster…
Arthritis | 22 June 2011
-
Rheumatoid arthritis patients value personalised goal setting
UCB announced data that showed patients with rheumatoid arthritis (RA) believe that personalised goal setting can have a positive impact on their disease management. However, while the majority of patients surveyed (87%) agreed with this, almost as m…
Arthritis | 26 May 2011
-
FDA approves Actemra for the treatment of arthritis
Medicine offers a new option for children living with a rare and severe form of arthritis.
Arthritis | 18 April 2011
-
CBio Receives Approvals for Rheumatoid Arthritis Trials
Australian-based drug development company CBio has announced a milestone achievement in its research in the treatment of rheumatoid arthritis. Jason Yeates, MD, said that human research ethics committee approvals have been received for all Centra…
Arthritis | 18 March 2010
-
AstraZeneca and Pozen Release Data on Osteoarthritis Drug
AstraZeneca and Pozen have announced pivotal data from two clinical trials. The data demonstrated that patients that were at risk for developing Non-Steroidal Anti-Inflammatory Drug (NSAID)-associated gastric ulcers taking Vimovo (naproxen/esomeprazo…
Arthritis | 05 November 2009
-
GlaxoSmithKline and Genmab Announce Results for Rheumatoid Arthritis Study
GlaxoSmithKline (GSK) and Genmab have announced preliminary results from a Phase III study of ofatumumab administered intravenously for the treatment of Rheumatoid Arthritis (RA) in patients who have an inadequate response to methotrexate. The st…
Arthritis | 13 August 2009
-
Wyeth Receives Approval for Arthritis Drug
Wyeth has received approval from the Japanese Ministry of Health, Labor and Welfare to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to “Enbrel 25mg for SC Injection,†(etanercept). The company also received…
Arthritis | 23 July 2009
-
Arthritis Treatment Drug Receives Recommendation
Nitec Pharma’s lead product Lodotra has been recommended for European regulatory approval for the treatment of rheumatoid arthritis (RA) and associated morning stiffness. Germany was the reference member state and the drug is now also considered a…
Arthritis | 01 January 2009
-
Growth Opportunities for Actemra in the Rheumatoid Arthritis Market
Growth opportunities for Roche/ Chugai’s Actemra (marketed as RoActemra in Europe) will propel Roche to sixth position in the rheumatoid arthritis market by 2012, according to Decision Resources. One factor is the drug’s early market entry in…
Arthritis | 01 January 2009
-
Actemra shows to inhibit progression of joint destruction
Roche has announced that its new therapy Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA) – this is a critical measure of effectiveness of an RA treatment. Actemra was also f…
Arthritis | 05 November 2008
